📊 SNGX Key Takeaways
Is Soligenix, Inc.. (SNGX) a Good Investment?
Soligenix is in financial distress with revenue collapsed 85.8% YoY to $119.4K while operating losses of $2.9M persist, resulting in an unsustainable -$2.4M operating cash burn. At the current burn rate, the company's $6.0M cash runway extends only 2-3 quarters without revenue stabilization or significant operational restructuring.
Soligenix, Inc.. Key Strengths (SNGX)
- Zero long-term debt eliminates leverage risk
- Gross margin of 81.5% indicates viable product economics if revenue returns
- Current ratio of 1.81x provides adequate short-term liquidity buffer
SNGX Stock Risks: Soligenix, Inc.. Investment Risks
- Revenue cliff of -85.8% YoY represents loss of primary business operations
- Negative operating cash flow of -$2.4M per period indicates unsustainable cash depletion
- Operating losses of -$2.9M against $119.4K revenue signals operational unviability
- Zero insider Form 4 filings in 90 days reflects no insider confidence
- Pharmaceutical company with near-zero revenue faces existential viability questions
- Cash runway of 2-3 quarters at current burn rate without intervention
Key Metrics to Watch
- Quarterly revenue stabilization and recovery trajectory
- Monthly cash burn rate and runway extension
- New product launches or pipeline progression announcements
- Strategic alternatives or restructuring announcements
- Changes in insider shareholding activity
Soligenix, Inc.. (SNGX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Soligenix, Inc.. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
SNGX Profit Margin, ROE & Profitability Analysis
SNGX vs Healthcare Sector: How Soligenix, Inc.. Compares
How Soligenix, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Soligenix, Inc.. Stock Overvalued? SNGX Valuation Analysis 2026
Based on fundamental analysis, Soligenix, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Soligenix, Inc.. Balance Sheet: SNGX Debt, Cash & Liquidity
SNGX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Soligenix, Inc..'s revenue has declined by 95% over the 5-year period, indicating business contraction. The most recent EPS of $-4.98 indicates the company is currently unprofitable.
SNGX Revenue Growth, EPS Growth & YoY Performance
SNGX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $119.4K | -$1.7M | $-0.58 |
| Q2 2025 | $2.3K | -$1.6M | $-0.82 |
| Q1 2025 | $117.0K | -$1.9M | $-1.06 |
| Q3 2024 | $119.4K | -$1.7M | $-0.78 |
| Q2 2024 | $2.3K | -$1.6M | $-1.31 |
| Q1 2024 | $117.0K | -$1.0M | $-0.18 |
| Q3 2023 | $130.4K | -$1.7M | $-0.16 |
| Q2 2023 | $206.9K | -$1.6M | $-0.26 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Soligenix, Inc.. Dividends, Buybacks & Capital Allocation
SNGX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Soligenix, Inc.. (CIK: 0000812796)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SNGX
What is the AI rating for SNGX?
Soligenix, Inc.. (SNGX) has an AI grade of D with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SNGX's key strengths?
Claude: Zero long-term debt eliminates leverage risk. Gross margin of 81.5% indicates viable product economics if revenue returns.
What are the risks of investing in SNGX?
Claude: Revenue cliff of -85.8% YoY represents loss of primary business operations. Negative operating cash flow of -$2.4M per period indicates unsustainable cash depletion.
What is SNGX's revenue and growth?
Soligenix, Inc.. reported revenue of $119.4K.
Does SNGX pay dividends?
Soligenix, Inc.. does not currently pay dividends.
Where can I find SNGX SEC filings?
Official SEC filings for Soligenix, Inc.. (CIK: 0000812796) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SNGX's EPS?
Soligenix, Inc.. has a diluted EPS of $-0.28.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SNGX's fundamental grade?
Based on our AI fundamental analysis in May 2026, Soligenix, Inc.. has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SNGX stock overvalued or undervalued?
Valuation metrics for SNGX: ROE of -91.4% (sector avg: 15%), net margin of -2,366.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SNGX's AI grade for 2026?
Our dual AI analysis gives Soligenix, Inc.. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SNGX's free cash flow?
Soligenix, Inc..'s operating cash flow is $-2.4M, with capital expenditures of $5.9K. FCF margin is -1,980.1%.
How does SNGX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,366.5% (avg: 12%), ROE -91.4% (avg: 15%), current ratio 1.81 (avg: 2).